A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Eribulin (Primary) ; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 13 May 2016 Planned End Date changed from 1 Jul 2014 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top